Staphylococcal Infections Clinical Trial
— ScreenStaphOfficial title:
Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne
The nasal carriage of Staphylococcus aureus is a major risk factor of S. aureus infection,
notably in hemodialysis patients (HPs). Decolonization strategies were shown able to reduce
the rate of S. aureus infection in this category of patients although the risk of emergence
of antimicrobial resistance persists. Approximately one quarter of the general population is
colonized by S. aureus in the anterior part of the nostril (vestibulum nasi). Three main
categories of nasal carriers have been historically identified: persistent carriers (20%,
12-30%]), intermittent carriers (30%, [16-70%]) and non-carriers (50% [16-69%]). By contrast
to intermittent carriers and non-carriers, persistent nasal carriers have a higher risk of
S. aureus infection, especially in continuous peritoneal dialysis and in orthopedic surgery.
Persistent carriers are characterized by a higher nasal bacterial load, a longer duration of
carriage, a lower rate of exchange of S. aureus strains, and a particular affinity for the
carried strain. However, there is no consensual definition of this persistent carriage
state. In previous studies, 5 to 12 nasal sampling episodes were realized for a period
ranging from 5 weeks to 8 years. The index of carriage, corresponding to the number of
samples positive for S. aureus divided by the total number of samples, has been proposed to
standardize the definition of the carriage state. According to standard tools, it is almost
impossible to determine the nasal carriage state in routine practice.
Recently, an algorithm based on one or two quantitative cultures from nasal samples taken
within 2 days that was able to distinguish accurately persistent and non-persistent nasal
carriers of S. aureus has been described; only one nasal sample was needed in more than 9
cases out of 10. The aim of the present study was to assess prospectively the reliability of
this algorithm in clinical practice in a cohort of healthcare workers (HCWs) and HPs and to
check its ability for identifying patients with the highest risk of S. aureus infection
Status | Completed |
Enrollment | 160 |
Est. completion date | February 2013 |
Est. primary completion date | November 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 25 Years and older |
Eligibility |
Inclusion Criteria: - Healthy Volunteers or hemodialysis patients - carrier state of S. aureus unknown - written consent Exclusion Criteria: - chronic soft skin tissue infection due to S. aureus or eczema, - ongoing or completed antibiotic treatment for less than 15 days, - nasal decolonization by mupirocin or skin decolonization by antiseptic bath for at least 5 consecutive days in the previous year, - pregnancy, - HIV infection - hemostasis disorder. |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | CHU Saint-Etienne | Saint-Etienne |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Saint Etienne |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | S. aureus nasal carriage state | HPs and HCWs were sampled over a 10-week period using at least 7 and at most 12 sampling episodes. S. aureus persistent nasal carriers were defined by an index of carriage greater than or equal to 0.8 and S. aureus intermittent nasal carriers by a positive index of carriage lower than 0.8. An index of carriage is defined for each patients by the ratio : positive sample/total sample | 10-week period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01447407 -
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
|
Phase 1 | |
Recruiting |
NCT00518076 -
Staphylococcus Aureus Carriers Students Nursing Oxacillin Resistant
|
N/A | |
Completed |
NCT01324440 -
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
|
Phase 1 | |
Completed |
NCT00501150 -
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
|
N/A | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00063089 -
Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever
|
Phase 1/Phase 2 | |
Completed |
NCT00175370 -
Vancomycin Study: Treatment of Catheter Related Bloodstream Infection Caused by Coagulase Negative Staphylococcus
|
N/A | |
Recruiting |
NCT03456544 -
Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China
|
||
Terminated |
NCT01196169 -
Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty
|
Phase 4 | |
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT02640937 -
Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections
|
N/A | |
Completed |
NCT02971657 -
Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections
|
N/A | |
Completed |
NCT00303069 -
V710 First-In-Man (FIM) Study (V710-001)
|
Phase 1 | |
Completed |
NCT00156377 -
Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
|
Phase 4 | |
Completed |
NCT00631566 -
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
|
N/A | |
Completed |
NCT00113191 -
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
|
N/A | |
Completed |
NCT02782078 -
Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections
|
N/A | |
Completed |
NCT00859677 -
Immunologic Predisposition of HIV Patients to Develop Methicillin-Resistant Staphylococcus Aureus (MRSA) Colonization and Infection
|
||
Completed |
NCT00211900 -
Evaluation of Manufacturing Lot of StaphVAX
|
Phase 3 | |
Completed |
NCT02492958 -
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
|
Phase 2 |